CMS Biosimilars Guidance

CMS Biosimilars Guidance

Earlier this week the Centers for Medicare & Medicaid Services (CMS) issued four guidance documents detailing how Medicare Parts B and D as well as the Medicaid Drug Rebate Program will treat biosimilar therapies.

 Download CMS guidance documents.

We’ve updated our privacy policy, including to provide further detail about how we collect, protect, use, and share personal data. Click here to view the privacy policy.

Top